Modernizing Clinical Trials to Accelerate Access
Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA to revolutionize their trial process, addressing inefficiencies, enhancing accessibility and expediting results.
Conventional clinical trials require frequent in-person visits, adding logistical burdens that deter patient participation. Sites are overwhelmed with administrative tasks, from medication handling to extensive paperwork, diverting attention from patient care and research. Additionally, pharmaceutical manufacturers must allocate significant resources to managing site operations and participant logistics, stretching internal capacities and slowing trial progress.
A Patient-Centered Solution That Delivers the Trial to the Participant
By implementing EVERSANA’s Direct-to-Participant (DTP) Dispensing model, the manufacturer redefined the clinical trial experience. This approach enabled participants to receive medications directly at home or convenient locations like FedEx drop points or retail pharmacies, eliminating travel burdens and broadening trial accessibility.
This case study highlights how EVERSANA’s innovative DTP model transforms clinical trials, making participation easier, improving efficiency and ultimately helping life-changing therapies reach patients faster. Download the full case study below.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…